GlaxoSmithKline PLC and Pfizer Inc agreed to combine their consumer healthcare businesses in a joint venture controlled by the British pharmaceutical giant, paving the way for it to split into two companies.
Glaxo is to hold 68 percent of the new entity, which would have combined sales of US$12.7 billion.
The UK drugmaker said it plans to list the new business on the stock market within three years.
Glaxo shares surged as much as 5.7 percent in London trading, the most since March.
The transaction creates the world’s biggest supplier of over-the-counter medicines with brands of painkillers such as Advil and Panadol, and marks a shift from CEO Emma Walmsley’s stated strategy of keeping the steadily performing consumer and vaccine businesses under the same roof as the more volatile pharma operations.
The company yesterday said the deal sets a foundation to create two companies — one focused on pharma and vaccines, and the other on consumer health.
Glaxo, Pfizer and others are grappling with surging research costs to develop new medicines even as insurers and governments demand lower prices for the finished product. A separation would help focus resources on separate businesses with different needs.
Walmsley has been working to revitalize a lackluster pipeline of new drugs at Glaxo, culling programs to focus on those that look most likely to succeed and bringing in industry veteran Hal Barron to oversee research.
Earlier this month, Glaxo agreed to buy drugmaker Tesaro Inc for US$5.1 billion, expanding in cancer medicines for a price analysts deemed high.
The deal follows a move by Glaxo earlier this year to pay US$13 billion for Novartis AG’s stake in a consumer joint venture.
The enlarged company is to operate under the name GSK Consumer Healthcare and the Glaxo unit’s existing CEO, Brian McNamara, and its chief financial officer, Tobias Hestler, would assume those roles in the joint venture.
The transaction is expected to close in the second half of next year. After that, Pfizer said it plans to deconsolidate its share of the business, which might boost its operating margins.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained